A recent study on recurrent GBM highlighted that CAR T cell therapy showed early promise but nearly 50% relapse rates indicate a crucial role for immune response in outcomes. PMID:42296961, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00585-4 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
